Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 47-71

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiolitis obliterans; Cardioprotection; Collateral vessels; Polycythemia; Preconditioning; Retinopathy

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; OXYGEN;

ANIMAL; CARDIOVASCULAR DISEASE; DISEASE MODEL; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; WOUND HEALING;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1; MYOCARDIAL ISCHEMIA; NEOPLASMS; OXYGEN; WOUND HEALING;

EID: 84897019542     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104720     Document Type: Article

References (199)

1. Semenza GL, Wang GL. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12:5447-54
2. Wang GL, Semenza GL. 1995. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1230-37
3. Wang GL, Jiang BH, Rue EA, Semenza GL. 1995. Hypoxia-inducible factor 1 is a basic-helix-loophelix- PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92:5510-14
4. Jiang BH, Semenza GL, Bauer C, Marti HH. 1996. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. Cell Physiol. 271:1172-80
5. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1αregulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 94:4273-78
6. Flamme I, Frohlich T, von Reutern M, Kappel A, Damert A, Risau W. 1997. HRF, a putative basichelix- loop-helix-PAS domain transcription factor is closely related to hypoxia-inducible factor 1α and developmentally expressed in blood vessels. Mech. Dev. 63:51-60
7. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, et al. 1997. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem. 272:8581-93
8. Tian H, McKnight SL, Russell DW. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:72-82
9. Ivan M, KondoK, YangH, KimW, Valiando J, et al. 2001. HIFαtargeted forVHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464-68
10. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. 2001. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-72
11. Yu F, White SB, Zhao Q, Lee FS. 2001. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98:9630-35
12. Mahon PC, Hirota K, Semenza GL. 2001. FIH-1: a novel protein that interacts with HIF-1αand VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15:2675-86
13. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. 2002. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:1466-71
14. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. 2002. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-61
15. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, et al. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-69
16. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, et al. 2009. Integrative analysis of HIF binding and transactivation reveals its role inmaintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA 106:4260-65
17. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. 2011. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117:e207-17
18. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, et al. 2003. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93:1074-81
19. JiangBH, RueE, WangGL, RoeR, Semenza GL. 1996. Dimerization, DNAbinding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271:17771-78
20. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-13
21. SemenzaGL, Jiang BH, Leung SW, Passantino R, Concordet JP, et al. 1996. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271:32529-37
22. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. CellMetab. 3:177-85
23. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. 2006. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3:187-97
24. KaelinWGJr, Ratcliffe PJ. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30:393-402
25. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, et al. 2008. Digoxin and other cardiac glycosides inhibit HIF-1αsynthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 105:19579-86
26. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. 2009. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA 106:17910-15
27. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, et al. 1998. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12:149-62
28. Compernolle V, Brusselmans K, Franco D, Moorman A, Dewerchin M, et al. 2003. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor 1α. Cardiovasc. Res. 60:569-79
29. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, et al. 2006. Hypoxia-inducible factor 1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J. Biol. Chem. 281:25703-11
30. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, et al. 2007. Inter-society consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. 45(Suppl.):S5-7
31. Bosch-Marca M, Okuyama H, Wesley JB, Sarkar K, KimuraH, et al. 2007. Effects of aging and hypoxiainducible factor 1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ. Res. 101:1310-18
32. Ceradini DJ, Kulkarni AR, CallaghanMJ, TepperOM, Bastidas N, et al. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10:858-64
33. SimonMP, TournaireR, Pouyssegur J. 2008. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J. Cell. Physiol. 217:809-18
34. Schito L, Rey S, Tafani M, Zhang H, Wong CC, et al. 2012. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. USA 109:E2707-16
35. ChaturvediP, GilkesDM, Wong CCL, Kshitiz, LuoW, et al. 2013. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Investig. 123:189-205
36. KinnairdT, Stabile E, BurnettMS, Epstein SE. 2004. Bone marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ. Res. 95:354-63
37. Losordo DW, Dimmeler S. 2004. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part II: Cell-based therapies. Circulation 109:2692-97
38. Patel TH, Kimura H, Weiss CR, Semenza GL, Hofmann LV. 2005. Constitutively active HIF-1α improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc. Res. 68:144-54
39. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marca M, Semenza GL. 2009. Adenoviral transfer of HIF-1αenhances vascular responses to critical limb ischemia in diabetic mice. Proc. Natl. Acad. Sci. USA 106:18769-74
40. Rey S, Lee K, Wang CJ, Gupta K, Chen S, et al. 2009. Synergistic effect of HIF-1αgene therapy and HIF-1-Activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc. Natl. Acad. Sci. USA 106:20399-404
41. Rey S, Luo W, Shimoda LA, Semenza GL. 2011. Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue. Blood 117:4988-98
42. CreagerMA, Olin JW, Belch JJ, Moneta GL, HenryTD, et al. 2011. Effect of hypoxia-inducible factor 1α gene therapy on walking performance in patients with intermittent claudication. Circulation 124:1765-73
43. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125:e2-220
44. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. 2003. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-14
45. Nallamothu BK, Bradley EH, Krumholz HM. 2007. Time to treatment in primary percutaneous coronary intervention. N. Engl. J. Med. 357:1631-38
46. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, et al. 1991. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. Circulation 83:739-46
47. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S. 1992. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N. Engl. J. Med. 327:1825-31
48. Resar JR, Roguin A, Voner J, Nasir K, Hennebry TA, et al. 2005. Hypoxia-inducible factor 1α polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 128:787-91
49. Hlatky MA, Quertermous T, Boothroyd DB, Priest JR, Glassford AJ, et al. 2007. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. Am.Heart J. 154:1035-42
50. Duran J, Gotzens V, Carballo J, Martin E, Petit M, et al. 2012. The HIF1A C85T single nucleotide polymorphism influences the number of branches of the human coronary tree. Cardiology 121:156-59
51. Braunwald E, Kloner RA. 1985. Myocardial reperfusion: a double-edged sword? J. Clin. Investig. 76:1713-19
52. Eltzschig HK, Eckle T. 2011. Ischemia and reperfusion-from mechanism to translation. Nat. Med. 17:1391-401
53. Konstantinidis K, Whelan RS, Kitsis RN. 2012. Mechanisms of cell death in heart disease. Arterioscler. Thromb. Vasc. Biol. 32:1552-62
54. Abel ED. 2007. Glucose for the aging heart? Circulation 21:116:884-87
55. Faeh D, Gutzwiller F, Bopp M, Swiss Natl. Cohort Study Group. 2009. Lower mortality from coronary heart disease and stroke at higher altitudes in Switzerland. Circulation 120:495-501
56. Murry CE, Jennings RB, Reimer KA. 1986. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-36
57. Cai Z, Zhong H, Bosch-Marca M, Fox-Talbot K, Wang L, et al. 2008. Complete loss of ischemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1α. Cardiovasc. Res. 77:463-70
58. Sarkar K, Cai Z, Gupta R, Parajuli N, Fox-Talbot K, et al. 2012. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc. Natl. Acad. Sci. USA 109:10504-9
59. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. 2008. Hypoxia-inducible factor 1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118:166-75
60. Gao L, Chen Q, Zhou X, Fan L. 2012. The role of hypoxia-inducible factor 1 in atherosclerosis. J. Clin. Pathol. 65:872-76
61. JiangG, LiT, Qiu Y, Chen W, Lou Y. 2007.RNAinterference forHIF-1αinhibits foam cells formation in vitro. Eur. J. Pharmacol. 562:183-90
62. Sluimer JC, Gasc JM, van Wanroij JL, KistersN, Groeneweg M, et al. 2008. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J. Am. Coll. Cardiol. 51:1258-65
63. Ben-Shoshan J, Afek A, Maysel-Auslender S, Barzelay A, Rubinstein A, et al. 2009. HIF-1αoverexpression and experimental murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29:665-70
64. Sumbayev VV, Yasinska I, Oniku AE, Streatfield CL, Gibbs BF. 2012. Involvement of hypoxia-inducible factor 1 in the inflammatory responses of human LAD2 mast cells and basophils. PLoS ONE 7:e34259
65. Yu AY, Shimoda LA, IyerNV, Huso DL, Sun X, et al. 1999. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J. Clin. Investig. 103:691-96
66. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH. 2003. Heterozygous deficiency of hypoxia-inducible factor 2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J. Clin. Investig. 111:1519-27
67. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. 2001. Partial HIF-1αdeficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 281:202-8
68. WhitmanEM, Pisarcik S, LukeT, FallonM, Wang J, et al. 2008. Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 294:309-18
69. Pisarcik S, Maylor J, Lu W, Yun X, Undem C, et al. 2013. Activation of hypoxia-inducible factor 1 in pulmonary arterial smooth muscle cells by endothelin-1. Am. J. Physiol. Lung Cell. Mol. Physiol. 304:549-61
70. Wang J, Weigand L, LuW, Sylvester JT, Semenza GL, Shimoda LA. 2006. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ. Res. 98:1528-37
71. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL. 2006. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 291:941-49
72. Abud EM, Maylor J, Undem C, Punjabi A, Zaiman AL, et al. 2012. Digoxin inhibits development of hypoxic pulmonary hypertension in mice. Proc. Natl. Acad. Sci. USA 109:1239-44
73. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, et al. 2000. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. J. Am. Med. Assoc. 283:1829-36
74. Fletcher EC. 2000. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir. Physiol. 119:189-97
75. Prabhakar NR, Dick TE, Nanduri J, Kumar GK. 2007. Systemic, cellular and molecular analysis of chemoreflex-mediated sympathoexcitation by chronic intermittent hypoxia. Exp. Physiol. 92:39-44
76. Peng YJ, Yuan G, Ramakrishnan D, Sharma SD, Bosch-Marca M, et al. 2006. Heterozygous HIF-1α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J. Physiol. 577:705-16
77. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. 2008. Induction of HIF-1α expression by intermittent hypoxia: involvement ofNADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 217:674-85
78. Peng YJ, Nanduri J, Yuan G, Wang N, Deneris E, et al. 2009. NADPH oxidase is required for the sensory plasticity of the carotid body by chronic intermittent hypoxia. J. Neurosci. 29:4903-10
79. Nanduri J, Wang N, Yuan G, Khan SA, Souvannakitti D, et al. 2009. Intermittent hypoxia degrades HIF-2αvia calpains resulting in oxidative stress: implications for recurrent apnea-induced morbidities. Proc. Natl. Acad. Sci. USA 106:1199-204
80. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. 2005. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J. Biol. Chem. 280:4321-28
81. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. 2008. Induction of HIF-1α expression by intermittent hypoxia: involvement ofNADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 217:674-85
82. ScortegagnaM, DingK, Oktay Y, Gaur A, Thurmond F, et al. 2003. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 35:331-40
83. Peng YJ, Nanduri J, Khan SA, Yuan G, Wang N, et al. 2011. Hypoxia-inducible factor 2α (HIF-2α) heterozygous-nullmice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension. Proc. Natl. Acad. Sci. USA 108:3065-70
84. Drager LF, Yao Q, Hernandez KL, Shin M, Bevans-Fonti S, et al. 2013. Chronic intermittent hypoxia induces atherosclerosis via activation of adipose angiopoietin-like 4. Am. J. Respir. Crit. Care Med. 188:240-48
85. Mudd JO, Kass DA. 2008. Tackling heart failure in the twenty-first century. Nature 451:919-28
86. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, et al. 2007. P53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446:444-48
87. Krishnan J, Suter M, Windak R, Krebs T, Felley A, et al. 2009. Activation of a HIF-1α-PPARγ axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 9:521-24
88. Silter M, Kogler H, Zieseniss A, Wilting J, Schafer K, et al. 2010. Impaired Ca2+-handling inHIF-1α+/- mice as a consequence of pressure overload. Pflug. Arch. 459:569-77
89. WeiH, Bedja D, Koitabashi N, Xing D, Chen J, et al. 2012. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-βsignaling. Proc. Natl. Acad. Sci. USA 109:E841-50
90. Brem H, Tomic-Canic M, Entero H, Hanflik AM, Wang VM, et al. 2007. The synergism of age and db/db genotype impairs wound healing. Exp. Gerontol. 42:523-31
91. Botusan IR, Sunkari VG, Savu O, Catrina AI, Grunler J, et al. 2008. Stabilization of HIF-1αis critical to improve wound healing in diabetic mice. Proc. Natl. Acad. Sci. USA 105:19426-31
92. Mace KA, Yu DH, Paydar KZ, Boudreau N, Young DM. 2007. Sustained expression of HIF-1α in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen. 15:636-45
93. Liu L, Marti GP, Wei X, Zhang X, Zhang H, et al. 2008. Age-dependent impairment of HIF-1α expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J. Cell. Physiol. 217:319-27
94. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, et al. 2009. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc. Natl. Acad. Sci. USA 106:13505-10
95. Zhang X, Liu L, Wei X, Tan YS, Tong L, et al. 2010. Impaired angiogenesis and mobilization of circulating angiogenic cells in HIF-1α heterozygous-null mice after burn wounding. Wound Repair Regen. 18:193-201
96. Sarkar K, Rey S, Zhang X, Sebastian R, Marti GP, et al. 2012. Tie2-dependent knockout of HIF-1 impairs burn wound vascularization and homing of bone marrow-derived angiogenic cells. Cardiovasc. Res. 193:162-69
97. Wilkes DS. 2011. Chronic lung allograft rejection and airway microvasculature: Is HIF-1 the missing link? J. Clin. Investig. 121:2155-57
98. Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, et al. 2011. Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J. Clin. Investig. 121:2336-49
99. Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, et al. 2009. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc. Natl. Acad. Sci. USA 106:21276-81
100. Campochiaro PA. 2013. Ocular neovascularization. J. Mol. Med. 22:6537-48
101. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, et al. 1999. Hypoxia-inducible factor 1αis increased in ischemic retina: temporal and spatial correlation with VEGF expression. Investig. Ophthalmol. Vis. Sci. 40:182-89
102. Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, Campochiaro PA. 2010. Digoxin inhibits retinal ischemia-induced HIF-1αexpression and ocular neovascularization. FASEB J. 24:1759-67
103. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. 2006. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-31
104. Semenza GL. 2009. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 114:2015-19
105. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, et al. 2002. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 32:614-21
106. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, et al. 2006. Mutation of von Hippel- Lindau tumor suppressor and human cardiopulmonary physiology. PLoS Med. 3:e290
107. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, et al. 1999. Overexpression of hypoxiainducible factor 1αin common human cancers and their metastases. Cancer Res. 59:5830-35
108. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, et al. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumorassociated macrophages. Am. J. Pathol. 157:411-21
109. Vaupel P, Mayer A, Hockel M. 2004. Tumor hypoxia and malignant progression. Methods Enzymol. 381:335-54
110. Vaupel P, Hockel M, Mayer A. 2007. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal. 9:1221-35
111. Quintero M, Brennan PA, Thomas GJ, Moncada S. 2006. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor 1αin cancer: role of free radical formation. Cancer Res. 66:770-74
112. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, et al. 2007. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12:230-38
113. Jiang BH, Agani F, Passaniti A, Semenza GL. 1997. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:5328-35
114. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, et al. 2000. Modulation of hypoxia-inducible factor 1αexpression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541-45
115. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. 2001. HER2neu signaling increases the rate of hypoxia-inducible factor 1α(HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:3995-4004
116. Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-34
117. Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, et al. 2004. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23:3708-15
118. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. 1999. Reciprocal positive regulation of hypoxia-inducible factor 1αand insulin-like growth factor 2. Cancer Res. 59:3915-18
119. Raval RR, LauKW, TranMG, SowterHM, Mandriota SJ, et al. 2005. Contrasting properties of hypoxiainducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated renal cell carcinoma. Mol. Cell. Biol. 25:5675-86
120. Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, et al. 2005. Coexpression of erythropoietin and erythropoietin receptor in vonHippel-Lindau disease-Associated renal cysts and renal cell carcinoma. Clin. Cancer Res. 11:1059-64
121. Smith K, Gunaratnam L, MorleyM, Franovic A, Mekhail K, Lee S. 2005. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor 2-driven VHL-/- renal cancer. Cancer Res. 65:5221-30
122. Zagzag D, Krishnamachary B, Yee H, OkuyamaH, Chiriboga L, et al. 2005. Stromal cell-derived factor 1αandCXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: vonHippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65:6178-88
123. Franovic A, Holterman CE, Payette J, Lee S. 2009. Human cancers converge at the HIF-2αoncogenic axis. Proc. Natl. Acad. Sci. USA 106:21306-11
124. Cao Y, Guangqi E, Wang E, Pal K, Dutta SK, et al. 2012. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72:3912-18
125. Pescador N, Villar D, Cifuentes D, Garcia-Rocha M, Ortiz-Barahona A, et al. 2010. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase. PLoS ONE. 5:e9644
126. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481:380-84
127. Semenza GL. 2011. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb. Symp. Quant. Biol. 76:347-53
128. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, et al. 2011. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 108:19611-16
129. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, et al. 2007. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11:407-20
130. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. 2011. Generation of a mouse model of von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF-1α. Cancer Res. 71:6848-56
131. Folkman J, Kalluri R. 2004. Cancer without disease. Nature 427:787
132. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, et al. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14:34-44
133. Du R, Lu KV, Petritsch C, Liu P, Ganss R, et al. 2008. HIF-1αinduces the recruitment of bonemarrow- derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-20
134. LeeK, Qian DZ, Rey S, WeiH, Liu JO, SemenzaGL. 2009. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. USA 106:2353-58
135. Stoeltzing O, McCarty MF, Wey JS, Fan F, LiuW, et al. 2004. Role of hypoxia-inducible factor 1αin gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 96:946-56
136. Zou W. 2005. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer 5:263-74
137. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. 2012. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 3:21
138. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, et al. 2002. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor 1 mediates permeability changes in intestinal epithelia. J. Clin. Investig. 110:993-1002
139. Sitkovsky M, Ohta A. 2013. Targeting the hypoxia-Adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J. Mol. Med. 91:147-55
140. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, et al. 2011. Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475:226-30
141. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, et al. 2010. Macrophage expression of hypoxia-inducible factor 1α suppresses T cell function and promotes tumor progression. Cancer Res. 70:7465-75
142. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J, et al. 2010. HIF-1αregulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp.Med. 207:2439-53
143. Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, et al. 2009. The cooperative induction of hypoxia-inducible factor 1αand STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J. Immunol. 182:3510-21
144. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-67
145. Liao D, Corle C, Seagroves TN, Johnson RS. 2007. Hypoxia-inducible factor 1αis a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67:563-72
146. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, et al. 2011. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. USA 108:16369-74
147. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, et al. 2012. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. 90:803-15
148. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, et al. 2012. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31:1757-70
149. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. 2006. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 4:38
150. Gilkes D, Bajpai S, Wong CC, Chaturvedi P, Hubbi ME, et al. 2013. Procollagen lysyl hydroxylase 2 is essential for breast cancer metastasis. Mol. Cancer Res. 11:456-66
151. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, et al. 2006. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-26
152. Erler JT, Bennewith KL, Cox TR, LangG, BirdD, et al. 2009. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15:35-44
153. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. 1999. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237:97-132
154. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, et al. 2009. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 175:2159-70
155. Ran S, Volk L, Hall K, FlisterMJ. 2010. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17:229-51
156. Theodoropoulos VE, Lazaris AC, Sofras F, Gerzelis I, Tsoukala V, et al. 2004. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46:200-8
157. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, et al. 2012. Regulation of HIF-1αsignaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol. Ther. 18:858-70
158. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, et al. 2005. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. Br. J. Urol. Int. 95:425-31
159. Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, et al. 2011. Hypoxia-inducible factor 1αprotein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk. Res. 35:579-84
160. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, et al. 2004. Hypoxiainducible factor 1α/vascular endothelial growth factor axis in astrocytomas: associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 30:267-78
161. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. 2009. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15:501-13
162. Birner P, Gatterbauer B, OberhuberG, SchindlM, Rossler K, et al. 2001. Expression of hypoxia-inducible factor 1αin oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165-71
163. SchindlM, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, et al. 2002. Overexpression of hypoxia-inducible factor 1αis associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8:1831-37
164. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, et al. 2003. Levels of hypoxia-inducible factor 1α independently predict prognosis in patients with lymph node-negative breast carcinoma. Cancer 97:1573-81
165. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, et al. 2005. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 116:734-39
166. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. 2006. Hypoxia-inducible factor 1αexpression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin. Cancer Res. 12:4562-68
167. Kronblad A? , Jirstrom K, Ryden L, Nordenskjold B, Landberg G. 2006. Hypoxia inducible factor 1αis a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int. J. Cancer 118:2609-16
168. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, et al. 2007. HIF-1αand CA-IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer 120:1443-50
169. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, et al. 2008. Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res. Treat. 110:465-75
170. Rajaganeshan R, Prasad R, Guillou PJ, Poston G, Scott N, Jayne DG. 2008. The role of hypoxia in recurrence following resection of Dukes B colorectal cancer. Int. J. Colorectal Dis. 23:1049-55
171. Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, et al. 2009. Hypoxia-inducible factor 1αand -2α are expressed in most rectal cancers but only hypoxia-inducible factor 1αis associated with prognosis. Br. J. Cancer 100:1666-73
172. Schmitz KJ, Muller CI, Reis H, Alakus H, WindeG, et al. 2009. Combined analysis of hypoxia-inducible factor 1αand metallothionein indicates an aggressive subtype of colorectal carcinoma. Int. J. Colorectal Dis. 24:1287-96
173. Tzao C, Lee SC, Tung HJ, Hsu HS, HsuWH, et al. 2008. Expression of hypoxia-inducible factor (HIF) 1α and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis. Markers 25:141-48
174. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, et al. 2001. Expression of hypoxia-inducible factor 1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2911-16
175. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, et al. 2002. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-Andneck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53:1192-202
176. Schrijvers ML, van der Laan BF, de Bock GH, Pattje WJ, Mastik MF, et al. 2008. Overexpression of intrinsic hypoxia markers HIF-1α and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 72:161-69
177. Zhu GQ, Tang YL, Li L, Zheng M, Jiang J, et al. 2010. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma. Clin. Cancer Res. 16:4732-41
178. Morine Y, Shimada M, Utsunomiya T, Imura S, Ikemoto T, et al. 2011. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. Hepato-Gastroenterology 58:1439-44
179. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, et al. 2001. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85:881-90
180. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, OByrne KJ. 2004. Hypoxia-inducible factor 1α in non-small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 111:43-50
181. Birner P, SchindlM, Obermair A, Breitenecker G, OberhuberG. 2001. Expression of hypoxia-inducible factor 1αin epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7:1661-68
182. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, et al. 2007. Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: Nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38:1310-20
183. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, et al. 2008. Prognostic significance of hypoxiainducible factor 1α(HIF-1α) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer 8:335
184. Shibaji T, NagaoM, Ikeda N, Kanehiro H, Hisanaga M, et al. 2003. Prognostic significance of HIF-1α overexpression in human pancreatic cancer. Anticancer Res. 23:4721-27
185. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, et al. 2007. Expression of hypoxia-inducible factor 1α and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 30:1359-67
186. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. 2003. Hypoxiainducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 13:493-501
187. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, et al. 2007. Hypoxia-inducible factor 1αexpression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastrooesophageal adenocarcinomas. Br. J. Cancer 96:95-103
188. Takahashi R, Tanaka S, Hiyama T, Ito M, Kitadai Y, et al. 2003. Hypoxia-inducible factor 1αexpression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 10:797-802
189. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. 2000. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:4693-96
190. Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, et al. 2003. Significant correlation of hypoxiainducible factor 1αwith treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56:494-501
191. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI, Tumor Angiogen. Res. Group. 2002. Association of hypoxia-inducible factors 1αand 2αwith activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-63
192. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, et al. 2005. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143-53
193. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261-65
194. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, et al. 2009. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106:11137-42
195. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, et al. 2006. PML inhibits HIF-1αtranslation and neoangiogenesis through repression of mTOR. Nature 442:779-85
196. ZundelW, Schindler C, Haas-Kogan D, Koong A, Kaper F, et al. 2000. Loss of PTEN facilitates HIF- 1-mediated gene expression. Genes Dev. 14:391-96
197. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, et al. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-αprolyl hydroxylase. Cancer Cell 7:77-85
198. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-58
199. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. 1999. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-75